This morning, the Supreme Court heard arguments in cases challenging FDA approval of abortion drug mifepristone.
The fact that many of the justices, including conservatives, were calling out the issue of standing and the plaintiffs’ legal ability to bring the case is a welcome sign for abortion rights advocates.
The court is considering whether the FDA overlooked safety in easing prescribing rules around the medication and whether a Fifth Circuit Court ruling rolling back the agency’s regulation should be allowed to stand. Advocates for the drug argued if that ruling did stand, future petitioners could file litigation to second-guess any of the FDA’s expertise in previous approvals of other drugs and therapeutics, setting a new precedent for federal judges to review any medication.
The case also bears on reproductive rights across the country, as abortion bans in 21 states have led to an increased dependence on telemedicine and mifepristone prescriptions. Allowing medication abortions to move forward without an in-person medical visit has increased access, allowing for women, particularly in rural areas, to receive care from home.
Justices Alito and Thomas seemed poised to uphold the Fifth Circuit Court opinion. Justices Barrett and Kavanaugh are expected to be swing votes on the case, with Barrett’s notable questioning of the plaintiffs’ standing specifically raising questions about how she might vote. It is not clear exactly when the Court will release its decision, but it is likely to come at the end of the court’s term in late June or early July.